Search results: Sage Journals

Restricted accessResearch articleFirst published May, 2011

Second-line chemotherapy with irinotecan,5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: Lessons from clinical practice

Mirco Pistelli, Mario Scartozzi, Alessandro Bittoni [...]

Tumori Journal

Open accessResearch articleFirst published January, 2020

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Jiaqi Han, Desheng Xiao, Chongqing Tan [...]

Cancer Control

Open accessResearch articleFirst published 2022

FOLFIRI (folinic acid,fluorouracil,and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial

Xiaowei Zhang, Ran Duan, Yusheng Wang [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2025

Efficacy and safety of regorafenib plus FOLFIRI with UGT1A1 genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter,phase II,open-label,two-arm randomized controlled tria

Ching-Wen Huang, Yen-Cheng Chen, Tao-Wei Ker [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published May, 2010

Pharmacoeconomic Aspects of FOLFIRI or FOLFOX Regimens Administered with a Fully Ambulatory Pump Compared to the Day Hospital Setting

Marco Tampellini

Tumori Journal

Restricted accessCase reportFirst published September, 2023

FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy

Elif Sertesen, Ali Öztaş, Cengiz Karaçin [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published November, 2021

The Correlation Between UGT1A1 Gene Phenotypes and the Clinical Prognosis of Advanced Colorectal Cancer After FOLFIRI Therapy

Xiao-Kai Li, Wen-Ling Wang, Yu-Xuan Xu [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessResearch articleFirst published 2020

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Francesca Foschini, Fabiana Napolitano, Alberto Servetto [...]

Therapeutic Advances in Medical Oncology

Restricted accessCase reportFirst published October, 2018

Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report

Satoru Mitsuboshi, Hiromi Kozakai, Hitoshi Yamada [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2021

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

Alessandro Ottaiano, Stefania Scala, Mariachiara Santorsola [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published May, 2011

Second-line chemotherapy with irinotecan,5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: Lessons from clinical practice

Mirco Pistelli, Mario Scartozzi, Alessandro Bittoni [...]

Tumori Journal

Open accessResearch articleFirst published January, 2020

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Jiaqi Han, Desheng Xiao, Chongqing Tan [...]

Cancer Control

Open accessResearch articleFirst published 2022

FOLFIRI (folinic acid,fluorouracil,and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial

Xiaowei Zhang, Ran Duan, Yusheng Wang [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2025

Efficacy and safety of regorafenib plus FOLFIRI with UGT1A1 genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter,phase II,open-label,two-arm randomized controlled tria

Ching-Wen Huang, Yen-Cheng Chen, Tao-Wei Ker [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published May, 2010

Pharmacoeconomic Aspects of FOLFIRI or FOLFOX Regimens Administered with a Fully Ambulatory Pump Compared to the Day Hospital Setting

Marco Tampellini

Tumori Journal

Restricted accessCase reportFirst published September, 2023

FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy

Elif Sertesen, Ali Öztaş, Cengiz Karaçin [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published November, 2021

The Correlation Between UGT1A1 Gene Phenotypes and the Clinical Prognosis of Advanced Colorectal Cancer After FOLFIRI Therapy

Xiao-Kai Li, Wen-Ling Wang, Yu-Xuan Xu [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessResearch articleFirst published 2020

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Francesca Foschini, Fabiana Napolitano, Alberto Servetto [...]

Therapeutic Advances in Medical Oncology

Restricted accessCase reportFirst published October, 2018

Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report

Satoru Mitsuboshi, Hiromi Kozakai, Hitoshi Yamada [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2021

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

Alessandro Ottaiano, Stefania Scala, Mariachiara Santorsola [...]

Therapeutic Advances in Medical Oncology